Nagaraja Narayana, Poddar S D, Rai Seema, Verma Vishesh, Abhisheka Kumar, Khurana Abha
Assisted Reproductive Technology (ART) Centre, Command Hospital Southern Command, Pune, India.
Department of Obstetrics and Gynaecology, Command Hospital Southern Command, Pune, India.
J Obstet Gynaecol India. 2023 Aug;73(4):351-357. doi: 10.1007/s13224-023-01813-4. Epub 2023 Aug 12.
Infertile women undergoing frozen embryo transfer (FET) cycles may not show optimal endometrial growth with estrogens alone.
To evaluate clinical effect of mild stimulation with letrozole and estrogens on endometrial growth in comparison to standard endometrial preparation with oral and topical estrogens in infertile women with unresponsive thin endometrium undergoing FET.
Retrospective observational case-control study.
Forty women unresponsive to first AC-FET cycle were given mild stimulation with letrozole and estrogens as second LE-FET cycle for endometrial preparation (LE-FET study group) and compared with 40 historical controls who had received two cycles of AC-FET (AC-FET control group). Responses were assessed by optimal endometrial thickness (≥ 7 mm) and clinical pregnancy.
Descriptive statistics were elaborated by mean ± SD and percentages. Results were expressed by mean ± SD, unpaired t test for difference in endometrial thickness, chi square and Fisher exact test to compare the difference in pregnancy among both groups.
Mean endometrial thickness was significantly increased in LE-FET study group (6.68 ± 2.09 mm) versus AC-FET control group (5.35 ± 1.90 mm). Higher clinical pregnancy rate was noted in study group as compared to control group (35% versus 12.5%).
This study suggests that letrozole with estradiol (LE-FET) compared to estradiol alone (AC-FET) for second cycle significantly increased endometrial thickness and improved clinical pregnancy rates in women with unresponsive thin endometrium after first AC-FET cycle with estradiol alone. Addition of letrozole to estrogen upfront for FET cycles may enhance endometrial receptivity and might improve pregnancy outcomes.
接受冻融胚胎移植(FET)周期的不孕女性仅使用雌激素可能无法实现最佳的子宫内膜生长。
与使用口服和局部雌激素进行标准子宫内膜准备相比,评估来曲唑和雌激素轻度刺激对FET周期中子宫内膜反应不良的薄型子宫内膜不孕女性子宫内膜生长的临床效果。
回顾性观察病例对照研究。
40名对首次AC-FET周期无反应的女性在第二个LE-FET周期接受来曲唑和雌激素轻度刺激以进行子宫内膜准备(LE-FET研究组),并与40名接受两个周期AC-FET的历史对照者(AC-FET对照组)进行比较。通过最佳子宫内膜厚度(≥7mm)和临床妊娠评估反应情况。
描述性统计采用均值±标准差和百分比进行阐述。结果以均值±标准差表示,采用不成对t检验比较子宫内膜厚度差异,采用卡方检验和Fisher精确检验比较两组妊娠差异。
LE-FET研究组的平均子宫内膜厚度(6.68±2.09mm)显著高于AC-FET对照组(5.35±1.90mm)。与对照组相比,研究组的临床妊娠率更高(35%对12.5%)。
本研究表明,与单独使用雌二醇(AC-FET)相比,在第二个周期中使用来曲唑联合雌二醇(LE-FET)可显著增加子宫内膜厚度,并提高首次单独使用雌二醇进行AC-FET周期后子宫内膜反应不良的薄型子宫内膜女性的临床妊娠率。在FET周期中提前将来曲唑添加到雌激素中可能会增强子宫内膜容受性,并可能改善妊娠结局。